Displaying drugs 351 - 375 of 8039 in total
Fomepizole
Fomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.
Approved
Vet approved
Matched Description: … steps in the metabolism of ethylene glycol and methanol to their toxic metabolites. ... Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial …
Ubidecarenone
Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation. The ubidecarenone is...
Approved
Investigational
Nutraceutical
Matched Description: … From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of ... destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of …
Cerivastatin
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.[A669,L43942]
Approved
Withdrawn
Matched Description: … that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of …
Ceftaroline fosamil
Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria:
Acute bacterial skin and skin structure infections.
Community-acquired bacterial pneumonia.
Approved
Investigational
Matched Description: … Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections …
Pegaspargase
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia...
Approved
Investigational
Matched Description: … Therefore, the use of pegaspargase results in leukemic cell death. ... patients with hypersensitivity to native forms of L-asparaginase. ... However, leukemia cells have low levels of this enzyme and depend on exogenous sources. …
Calcifediol
The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
Approved
Nutraceutical
Matched Description: … The major circulating metabolite of vitamin D3 (cholecalciferol). ... It is produced in the liver and is the best indicator of the body's vitamin D stores. ... It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients …
Golimumab
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with...
Approved
Matched Description: … The FDA label includes a black box warning of serious infections and malignancy. …
Luliconazole
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Approved
Matched Description: … antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of …
Cefotetan
A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.
Approved
Matched Description: … of both aerobic and anaerobic gram-positive and gram-negative microorganisms. ... The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range …
Danicopan
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Matched Description: … [A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. …
Warfarin
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally,...
Approved
Matched Description: … biologically active forms of various clotting factors in addition to several regulatory factors. ... Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of …
Rilpivirine
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance...
Approved
Matched Description: … [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting ... Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of ... binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's …
Matched Categories: … Antivirals used in combination for the treatment of HIV infections …
Matched Categories: … Antivirals used in combination for the treatment of HIV infections …
Moxisylyte
Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. According to the WHO, moxisylyte is approved since 1987 and in the same year, it acquired the denomination of orphan product by the FDA. This drug was developed by the Japanese company Fujirebio and also...
Approved
Investigational
Matched Description: … the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of …
Methscopolamine bromide
A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Approved
Matched Description: … A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors. …
Cefoperazone
Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its...
Approved
Investigational
Matched Description: … It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections …
Tenapanor
Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and...
Approved
Investigational
Matched Description: … In October 2023, tenapanor was approved for the treatment of chronic kidney disease.[L48511] ... [A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first ... within its class[A185489,A185492,A185495] and therefore exists as a novel alternative in the treatment of …
Pantoprazole
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be...
Approved
Matched Description: … from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including ... This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of ... (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events …
Zolpidem
Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the...
Approved
Matched Description: … the number of awakenings during sleep in patients with temporary (transient) insomnia. ... profile is favorable when administered according to the manufacturer’s instructions, with a low risk of ... This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases …
Dicyclomine
Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small...
Approved
Matched Description: … Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of ... histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and ... A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of …
Asciminib
Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein which serves as a driver of CML proliferation in most patients with the disease....
Approved
Investigational
Matched Description: … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995 ... Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into ... ] which serves as a driver of CML proliferation in most patients with the disease. …
Deucravacitinib
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor ... tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this ... [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib …
Erythropoietin
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO...
Approved
Matched Description: … Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red ... It works by promoting the division and differentiation of committed erythroid progenitors in the bone ... glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of …
Andexanet alfa
Andexanet alfa is a recombinant human coagulation Factor Xa that promotes blood coagulation. It was developed by Portola Pharmaceuticals and was approved in in May 2018. It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with rivaroxaban and apixaban...
Approved
Investigational
Matched Description: … The procoagulation potential of andexanet alfa is eliminated through the removal of a 34-residue fragment ... It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of ... However, the use of these agents is associated with a risk for uncontrollable bleeding episodes that …
Inotersen
Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It was FDA approved in October 2018. Inotersen has been shown to improve the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis .
Hereditary transthyretin...
Approved
Investigational
Matched Description: … [L11761] Inotersen has been shown to improve the course of neurologic disease and quality of life in ... Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy ... in the gene encoding transthyretin (TTR), which lead to transthyretin misfolding and the deposition of …
Allogeneic processed thymus tissue
Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital athymia. As part of the immune system, the thymus is an organ responsible for the maturation and selection of T cells...
Approved
Matched Description: … As part of the immune system, the thymus is an organ responsible for the maturation and selection of ... reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of ... [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a …
Displaying drugs 351 - 375 of 8039 in total